trial · primary record
Ublituximab
Relapsing Multiple Sclerosis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 800 |
| Primary completion | 2027-01-21 |
| Primary endpoint | Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 |
| Registry ID | NCT05877963 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:21.213Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05877963
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.